Business Description
Amryt Pharma PLC
Share Class Description:
AMYT: ADRDescription
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | 2.41 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.44 | |||||
| Beneish M-Score | -3.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 111.16 | |||||
| 12-1 Month Momentum % | 88.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | |||||
| Quick Ratio | 0.94 | |||||
| Cash Ratio | 0.58 | |||||
| Days Inventory | 316.7 | |||||
| Days Sales Outstanding | 53.73 | |||||
| Days Payable | 324.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -91.1 | |||||
| Shareholder Yield % | -3.12 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.86 | |||||
| Operating Margin % | -18.5 | |||||
| Net Margin % | -0.32 | |||||
| FCF Margin % | 43.78 | |||||
| ROE % | -0.24 | |||||
| ROA % | -0.1 | |||||
| ROIC % | -4.71 | |||||
| 3-Year ROIIC % | 4.34 | |||||
| ROC (Joel Greenblatt) % | 204.32 | |||||
| ROCE % | 4.08 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 26.11 | |||||
| Price-to-Owner-Earnings | 7.12 | |||||
| PS Ratio | 3.98 | |||||
| PB Ratio | 2.9 | |||||
| Price-to-Free-Cash-Flow | 10.04 | |||||
| Price-to-Operating-Cash-Flow | 9.88 | |||||
| EV-to-EBIT | 40.96 | |||||
| EV-to-EBITDA | 12.14 | |||||
| EV-to-Forward-EBITDA | 13.61 | |||||
| EV-to-Revenue | 4.4 | |||||
| EV-to-Forward-Revenue | 3.47 | |||||
| EV-to-FCF | 10.05 | |||||
| Price-to-Projected-FCF | 3.63 | |||||
| Earnings Yield (Greenblatt) % | 2.44 | |||||
| FCF Yield % | 10.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMYT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amryt Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 243.621 | ||
| EPS (TTM) ($) | -0.3 | ||
| Beta | 0 | ||
| Volatility % | 102.71 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.029847 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 88.24 | ||
| 52-Week Range ($) | 6.41 - 14.77 | ||
| Shares Outstanding (Mil) | 64.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amryt Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amryt Pharma PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amryt Pharma PLC Frequently Asked Questions
What is Amryt Pharma PLC(AMYT)'s stock price today?
The current price of AMYT is $14.70. The 52 week high of AMYT is $14.77 and 52 week low is $6.41.
When is next earnings date of Amryt Pharma PLC(AMYT)?
The next earnings date of Amryt Pharma PLC(AMYT) is 2025-03-01 Est..
Does Amryt Pharma PLC(AMYT) pay dividends? If so, how much?
Amryt Pharma PLC(AMYT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers